Evidence map›Paper›PMID 39017899›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Comparing the risk of severe oral mucositis associated with methotrexate as graft-versus host-disease prophylaxis to other immunosuppressive prophylactic agents in hematopoietic cell transplantation: a systematic review and meta-analysis.

Aisha A H Al-Jamaei, Joel B Epstein, Jan G A M de Visscher, Ricardo T Spielberger, Ryotaro Nakamura, Judith E Raber-Durlacher

Abstract readComparative StudyMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aisha A H Al-JamaeiDepartment of Oral and Maxillofacial Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
Joel B EpsteinCedars-Sinai Medical Center, Los Angeles, CA, USA.
Jan G A M de VisscherDepartment of Oral and Maxillofacial Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
Ricardo T SpielbergerDepartment of BMT, Southern California Permanente Medical Group, Kaiser Permanente, Los Angeles, CA, USA.
Ryotaro NakamuraDepartment of Hematology &, Center for Stem Cell Transplantation at City of Hope Comprehensive Cancer Center, Hematopoietic Cell Transplantation, Duarte, CA, USA.
Judith E Raber-DurlacherDepartment of Oral and Maxillofacial Surgery, Amsterdam UMC, Amsterdam, The Netherlands. j.raber.durlacher@acta.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study examines the risk of severe oral mucositis (SOM) in graft-versus-host disease prophylaxis (GVHD) compared to other agents in hematopoietic cell transplantation patients.

methodsA comprehensive search of four databases, including PubMed, Embassy, Web of Science, and Scopus, was conducted to identify studies reporting frequency and severity of oral mucositis in association with GVHD prophylactic regimens. RevMan 5.4 was used to perform the meta-analysis. Risk of bias assessment was carried out using the Rob-2 tool for randomized clinical trials (RCTs) and ROBINS-I tool for observational studies.

resultsTwenty-five papers, including 11 RCTs and 14 observational studies, met the inclusion criteria. The pooled results from eight RCTs showed a higher risk of SOM in patients receiving MTX or MTX-inclusive GVHD prophylaxis versus non-MTX alternatives (RR = 1.50, 95% CI [1.20, 1.87], I

conclusionPatients receiving MTX have a higher SOM risk compared to other approaches to prevent GVHD, which should be considered in patient care. When appropriate, MMF, FA, and a mini-dose of MTX may be an alternative that is associated with less SOM. This work also underlines the scarcity of RCTs on MTX interventions to provide the best evidence-based recommendations.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunosuppressive AgentsMethotrexateStomatitisHumansRandomized Controlled Trials as TopicSeverity of Illness IndexImmunosuppressive AgentsMethotrexateGraft versus host diseaseHCTHematopoietic cell transplantationMethotrexateOral mucositis

Identifiers

PMID39017899
PMCPMC11255043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.